52-Week results from IXORA-S: a randomized head-to-head trial of ixekizumab and ustekinumab in patients with moderate-to-severe plaque psoriasis

被引：0
|
作者：
Paul, C. [1 ]
van de Kerkhof, P. [2 ]
Dutronc, Y. [3 ]
Henneges, C. [3 ]
Dossenbach, M. [3 ]
Hollister, K. [3 ]
Reich, K. [4 ,5 ]
机构：
[1] Paul Sabatier Univ, CHU, Dermatol, Toulouse, France
[2] Radboud Univ Nijmegen, Med Ctr, Dept Dermatol, Nijmegen, Netherlands
[3] Eli Lilly & Co, Indianapolis, IN 46285 USA
[4] Dermatol Hamburg, Hamburg, Germany
[5] SCIderm Res Inst, Hamburg, Germany
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2017年 / 177卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P094
引用
收藏
页码：E293 / E293
页数：1
相关论文
共 50 条
  • [21] Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
    Boni E. Elewski
    Andrew Blauvelt
    Gaia Gallo
    Eric Wolf
    Missy McKean-Matthews
    Russel Burge
    Joseph F. Merola
    Alice B. Gottlieb
    Lyn C. Guenther
    Dermatology and Therapy, 2022, 12 : 911 - 920
  • [22] Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
    Elewski, Boni E.
    Blauvelt, Andrew
    Gallo, Gaia
    Wolf, Eric
    McKean-Matthews, Missy
    Burge, Russel
    Merola, Joseph F.
    Gottlieb, Alice B.
    Guenther, Lyn C.
    DERMATOLOGY AND THERAPY, 2022, 12 (04) : 911 - 920
  • [23] Efficacy and safety of continuous every-2-week dosing of ixekizumab over 52 weeks in patients with moderate-to-severe plaque psoriasis in a randomized phase III trial (IXORA-P)
    Langley, R. G.
    Papp, K.
    Gooderham, M.
    Zhang, L.
    Mallinckrodt, C.
    Agada, N.
    Blauvelt, A.
    Foley, P.
    Polzer, P.
    BRITISH JOURNAL OF DERMATOLOGY, 2018, 178 (06) : 1315 - 1323
  • [24] The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE)
    Reich, K.
    Gooderham, M.
    Green, L.
    Bewley, A.
    Zhang, Z.
    Khanskaya, I.
    Day, R. M.
    Goncalves, J.
    Shah, K.
    Piguet, V.
    Soung, J.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (03) : 507 - 517
  • [25] Efficacy of ixekizumab vs. adalimumab in patients with psoriatic arthritis with moderate-to-severe psoriasis: 52-week results from a multicentre, randomized, open-label study
    Kleyn, C. E.
    Gooderham, M.
    Kristensen, L. E.
    de Vlam, K.
    Schuster, C.
    Leage, S. Liu
    McKenzie, R.
    Sapin, C.
    Li, L.
    Griffiths, C. E. M.
    BRITISH JOURNAL OF DERMATOLOGY, 2020, 183 : 70 - 71
  • [26] Simultaneous nail and skin clearance in 5 ixekizumab head-to-head trials for moderate-to-severe psoriasis and psoriatic arthritis
    Elewski, Boni E.
    Blauvelt, Andrew
    Gallo, Gaia
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB110 - AB110
  • [27] Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate-to-severe plaque psoriasis: 52-week results from the CLEAR study
    Blauvelt, A.
    Reich, K.
    Mehlis, S.
    Vanaclocha, F.
    Sofen, H.
    Abramovits, W.
    Zhao, Y.
    Gilloteau, I.
    Davenport, E.
    Williams, N.
    Guana, A.
    Tyring, S.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (10) : 1693 - 1699
  • [28] Efficacy of tofacitinib for the treatment of nail psoriasis: Two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis
    Merola, Joseph F.
    Elewski, Boni
    Tatulych, Svitlana
    Lan, Shuping
    Tallman, Anna
    Kaur, Mandeep
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 77 (01) : 79 - +
  • [29] Effectiveness of ixekizumab for the treatment of moderate-to-severe plaque psoriasis with involvement of difficult-to-treat areas: A 52-week multicenter retrospective study
    Valenti, Mario
    Gargiulo, Luigi
    Ibba, Luciano
    Cortese, Andrea
    Toso, Francesco
    Orsini, Diego
    Lora, Viviana
    Frascione, Pasquale
    Sena, Paolo
    Carugno, Andrea
    Assorgi, Chiara
    Costanzo, Antonio
    Narcisi, Alessandra
    JOURNAL OF DERMATOLOGY, 2024, 51 (06): : 839 - 843
  • [30] EFFICACY OF IXEKIZUMAB VERSUS ADALIMUMAB IN PSORIATIC ARTHRITIS (PSA) PATIENTS WITH AND WITHOUT MODERATE-TO-SEVERE PSORIASIS: 52-WEEK RESULTS FROM A MULTICENTRE, RANDOMIZED OPEN-LABEL STUDY
    Kristensen, Lars-Erik
    Okada, Masato
    Tillett, William
    Leage, Soyi Liu
    El Baou, Celine
    Bradley, Andrew
    Moszaros, Gabriella
    De Vlam, Kurt
    Mora Alfonso, Sergio Alexander
    JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2021, 27 : S140 - S141
12345